Tarsus Pharmaceuticals (NASDAQ:TARS) Sets New 1-Year High - Here's What Happened
Tarsus Pharmaceuticals (NASDAQ:TARS) reached a new 52-week high of $57.14 during trading, closing at $56.17. Analysts have raised price targets, with Oppenheimer increasing theirs to $65.00 and Goldman Sachs to $41.00. The stock has a consensus rating of "Buy" and an average price target of $54.20. Institutional investors hold 90.01% of the stock, and the company focuses on developing treatments for eye care, notably its lead product XDEMVY for blepharitis.
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report)'s stock price reached a new 52-week high during trading on Monday . The stock traded as high as $57.14 and last traded at $56.17, with a volume of 228758 shares trading hands. The stock had previously closed at $55.00.
Get Tarsus Pharmaceuticals alerts:
Wall Street Analysts Forecast Growth
A number of brokerages have issued reports on TARS. Oppenheimer lifted their price target on Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the stock an "outperform" rating in a report on Thursday, November 14th. The Goldman Sachs Group upped their price target on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a "neutral" rating in a report on Friday, November 15th. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $54.20.
Read Our Latest Report on TARS
Tarsus Pharmaceuticals Price Performance
The firm has a market capitalization of $2.14 billion, a PE ratio of -14.67 and a beta of 1.04. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. The company has a fifty day moving average price of $48.24 and a two-hundred day moving average price of $35.82.
Institutional Investors Weigh In On Tarsus Pharmaceuticals
A number of institutional investors and hedge funds have recently added to or reduced their stakes in TARS. Quest Partners LLC acquired a new position in shares of Tarsus Pharmaceuticals in the 2nd quarter valued at $61,000. Canada Pension Plan Investment Board acquired a new position in Tarsus Pharmaceuticals in the second quarter valued at $114,000. FMR LLC increased its stake in Tarsus Pharmaceuticals by 236.6% in the third quarter. FMR LLC now owns 5,032 shares of the company's stock valued at $166,000 after purchasing an additional 3,537 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Tarsus Pharmaceuticals by 33.4% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company's stock valued at $166,000 after buying an additional 1,530 shares during the last quarter. Finally, SG Americas Securities LLC boosted its stake in shares of Tarsus Pharmaceuticals by 87.5% during the third quarter. SG Americas Securities LLC now owns 7,242 shares of the company's stock worth $238,000 after buying an additional 3,379 shares during the period. Hedge funds and other institutional investors own 90.01% of the company's stock.
Tarsus Pharmaceuticals Company Profile
(Get Free Report)Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
Featured Stories
- Five stocks we like better than Tarsus Pharmaceuticals
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- 3 Must-Hold Stocks with Double-Digit Upside for 2025
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Micron: Why Now Is the Time to Be Brave
- How to Invest in the FAANG Stocks
- 3 Stocks That Wall Street Insiders Can’t Stop Buying
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
→ Viral Trump video released (From Porter & Company) (Ad)
Should you invest $1,000 in Tarsus Pharmaceuticals right now?
Before you consider Tarsus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tarsus Pharmaceuticals wasn't on the list.
While Tarsus Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
